Trial · NCT01285037
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended dose for phase 2 studies: Maximum tolerated dose | Baseline to study completion (estimated as 3 months) | |
| Secondary | Number of participants with tumor response | Part A: Baseline to study completion (estimated as 3 months) | |
| Secondary | Clinical benefit rate (CBR) | Parts B, C, D: Baseline to study completion (estimated as 3 months) | |
| Secondary | Progression free survival (PFS) | Parts B, C, D: Baseline to study completion (estimated as up to 6 months) | |
| Secondary | Duration of response | Parts B, C, D: Baseline to study completion (estimated as up to 6 months) | |
| Secondary | Number of participants with clinically significant effects | Baseline to study completion (estimated as 3 months) | |
| Secondary | Pharmacokinetics: Area under the concentration/time curve (AUC) | Cycle 1, Day 1; Cycle 2, Day 1 | |
| Secondary | Pharmacokinetics: Maximum plasma concentration (Cmax) | Cycle 1, Day 1; Cycle 2, Day 1 | |
| Secondary | Maximum tolerated dose (MTD) of LY2801653 in combination with cetuximab for phase 2 studies in HNSCC | Baseline to study completion (estimated as 3 months) | |
| Secondary | Maximum tolerated dose (MTD) of LY2801653 in combination with cisplatin for phase 2 studies in cholangiocarcinoma | Baseline to study completion (estimated as 3 months) | |
| Secondary | Maximum tolerated dose (MTD) of LY2801653 in combination with gemcitabine plus cisplatin for phase 2 studies in cholangiocarcinoma | Baseline to study completion (estimated as 3 months) | |
| Secondary | Maximum tolerated dose (MTD) of LY2801653 in combination with ramucirumab for phase 2 studies in gastric carcinoma | Baseline to study completion (estimated as 3 months) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01285037/registered